GH Research PLC Stock
GH Research PLC Stock price
Key metrics
| Market capitalization | $472.94m |
| Enterprise Value | $323.63m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 2.50 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-48.48m |
| Cash position | $151.32m |
| EPS (TTM) EPS | $-0.80 |
| P/E forward | negative |
Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
GH Research PLC Stock Analysis
Analyst Opinions
5 Analysts have issued a GH Research PLC forecast:
Analyst Opinions
5 Analysts have issued a GH Research PLC forecast:
Financial data from GH Research PLC
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.32 -0.32 |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -48 -48 |
24%
24%
|
| Net Profit | -41 -41 |
1%
1%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GH Research PLC Stock News
Company Profile
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
| Head office | Ireland |
| CEO | Villy Valcheva |
| Employees | 49 |
| Founded | 2021 |
| Website | www.ghres.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
